Academic Article
RDF
pages:
-
A phase i clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer
-
A Phase I Clinical Trial of Murine Monoclonal Antibody D612 in Patients with Metastatic Gastrointestinal Cancer
-
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
-
A Phase I dose-escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignancies
-
A phase i dosing study of ferumoxytol for MR lymphography at 3 T in patients with prostate cancer
-
A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1
-
A phase I evaluation of intravenous (IV) (131)I-chlorotoxin delivery to solid peripheral and intracranial tumors.
-
A phase I evaluation of intravenous TM601 in recurrent glioblastoma: Use of perfusion MRI to monitor antiangiogenic effects.
-
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting
-
A Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects
-
A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome
-
A phase i study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer
-
A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
-
A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma
-
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases
-
A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
-
A phase I study of combined modality90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer
-
A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer
-
A Phase I study of high-dose cisplatin, prolonged infusion 5- fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous cell carcinoma of the head and neck
-
A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck
-
A phase I study of T101-ricin a chain immunotoxin in refractory chronic lymphocytic leukemia
-
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas
-
A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer
-
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects
-
A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors
-
A phase I-II trial to examine the toxicity of CMV- and EVB-specific cytotoxic T lymphocytes when used for prophylaxis against EVB and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants
-
A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)
-
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma
-
A phase II breast cancer chemoprevention trial of oral α-difluoromethylornithine: Breast tissue, imaging, and serum and urine biomarkers
-
A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma
pages:
